Home / Stocks / Best Health Services Stocks

10 Best Health Services Stocks to Buy in 2026

Data-driven analysis of 19 health services stocks ranked by Tradestie Score

Updated
19 stocks analyzed
5 min read
19
Stocks Analyzed
55.1
Avg. Score
$14B
Total Market Cap
66.5
Top Score
Jan 05, 2026
Last Updated
The Health Services sector remains a cornerstone for investors amid an aging global population and rising healthcare expenditures, which are projected to exceed $10 trillion annually by 2025, offering defensive growth potential in uncertain economic climates. Technological advancements, such as telehealth and AI-driven diagnostics, are accelerating sector innovation, making it attractive for long-term portfolios. With post-pandemic shifts emphasizing mental and preventive care, stocks in this sector demonstrate resilience and upside potential based on strong demand fundamentals.

Top 3 Picks

2
DCGO
DocGo Inc. Common Stock
63.7
Tradestie
Score
View Analysis
3
LFST
LifeStance Health Group, Inc. Common Stock
62.7
Tradestie
Score
View Analysis

2026 Outlook

Key trends in the Health Services sector include the rapid adoption of digital health solutions and expanded mental health services, driven by demographic shifts and regulatory support, positioning the sector for sustained growth. By 2026, industry revenue is expected to grow at a 5-7% CAGR, fueled by telemedicine penetration reaching over 30% of consultations and increased focus on value-based care models. However, potential challenges like reimbursement pressures and staffing shortages could temper gains, though overall optimism persists due to robust demand from an aging population exceeding 1.5 billion people aged 65+ worldwide.

Complete Rankings

Rank Stock Score Price Market Cap
1
US Physical Therapy Inc
66.5 $84.10 $1.3B
2
DocGo Inc. Common Stock
63.7 $0.90 $128M
3
LifeStance Health Group, Inc. Common Stock
62.7 $7.09 $2.1B
4
Talkspace, Inc. Common Stock
60.9 $3.65 $452M
5
Agape ATP Corporation Common Stock
58.7 $0.10 $61M
6
P3 Health Partners Inc. Warrant
57.6 $0.01 --
7
VSee Health, Inc. Common Stock
56.1 $0.43 $10M
8
EUDA Health Holdings Limited Ordinary Shares
56.0 $2.39 $74M
9
The Pennant Group, Inc. Common Stock
56.0 $28.44 $878M
10
Omada Health, Inc. Common Stock
54.3 $15.00 $1.3B
11
WGS
GeneDx Holdings Corp. Class A Common Stock
54.2 $133.32 $3.3B
12
InnovAge Holding Corp. Common Stock
53.6 $5.38 $704M
13
Kindly MD, Inc. Common Stock
53.5 $0.51 $467M
14
P3 Health Partners Inc. Common Stock
53.1 $3.98 $29M
15
Privia Health Group, Inc. Common Stock
52.3 $24.19 $3.1B

In-Depth Analysis: Top Health Services Stocks

1

USPH

US Physical Therapy Inc
66.5
Score
$84.10
$1.3B
Company Overview

US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating …

Why This Matters

US Physical Therapy Inc. matters in the Health Services sector as it provides specialized outpatient physical therapy services for orthopedic, sports, and neurological injuries, addressing a growing demand driven by an aging population and increasing injury rates. Its network of clinics enhances accessibility to preventative and rehabilitative care, positioning it as a key contributor to efficient healthcare delivery.

Profitability Analysis

USPH's profitability is moderate, with a 5.9% profit margin indicating efficient cost management in a competitive sector, while an 8.4% ROE reflects reasonable returns on shareholder equity. The 17.3% revenue growth demonstrates strong financial health and operational expansion, though the 33.3 P/E ratio suggests the stock is priced for future growth amid potential margin pressures.

5.9%
Profit Margin
8.4%
ROE
17.3%
Revenue Growth
33.3
P/E Ratio
Why It's a Buy in 2026

Investors should consider buying USPH stock in 2026 due to its 17.3% revenue growth, which signals continued expansion in the physical therapy market fueled by rising healthcare needs. The Tradestie Score of 66.5/100 indicates a solid investment potential, and with a 33.3 P/E ratio, the company is well-positioned for valuation appreciation as demand for outpatient services grows. Additionally, demographic trends like an aging population could further boost revenue, making USPH a compelling long-term hold.

2

DCGO

DocGo Inc. Common Stock
63.7
Score
$0.90
$128M
Company Overview

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes …

Why This Matters

DocGo Inc. matters in the Health Services sector as a leader in last-mile mobile health services and integrated medical mobility solutions, addressing critical needs for on-demand healthcare delivery and virtual care management. Its three reporting segments, including Mobile Health Services and Transportation, enhance accessibility and efficiency in an industry increasingly focused on telehealth innovations.

Profitability Analysis

DocGo's negative profit margin of -14.0% and return on equity of -21.1% indicate ongoing unprofitability and inefficient use of shareholders' equity, reflecting challenges in cost management or revenue generation. The steep revenue growth decline of -48.9% further highlights potential operational or market-related weaknesses, though the Tradestie Score of 63.7 suggests moderate overall financial appeal.

-14.0%
Profit Margin
-21.1%
ROE
-48.9%
Revenue Growth
Why It's a Buy in 2026

By 2026, DocGo could benefit from the projected growth in telehealth and mobile health services, with its platform potentially driving recovery from the -48.9% revenue decline as demand for integrated care solutions rises. The Tradestie Score of 63.7 indicates a foundation for investment appeal, supported by sector trends like increasing adoption of virtual care. If DocGo effectively addresses its current financial challenges, such as improving profitability from -14.0%, it may achieve significant upside in a expanding health services market.

3

LFST

LifeStance Health Group, Inc. Common Stock
62.7
Score
$7.09
$2.1B
Company Overview

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.

Why This Matters

LifeStance Health Group matters in the Health Services sector as a dedicated provider of outpatient mental health services, addressing a critical gap in accessible psychiatric evaluations, therapy, and testing amid rising global demand for mental health care. Its single operating segment enables efficient scaling and focus on this high-growth area, positioning it as a key player in expanding mental health accessibility.

Profitability Analysis

LifeStance's profitability is currently weak, with a negative profit margin of -0.7% and ROE of -0.6%, indicating challenges in generating profits and returns on equity despite operational activities. However, the company's strong revenue growth of 16.3% suggests potential for improved financial health if it can effectively manage costs and scale operations.

-0.7%
Profit Margin
-0.6%
ROE
16.3%
Revenue Growth
Why It's a Buy in 2026

LFST's robust 16.3% revenue growth highlights its ability to capitalize on the expanding mental health market, which is projected to grow significantly by 2026 due to increasing awareness and demand for services. The Tradestie Score of 62.7 indicates moderate upside potential, supported by the company's focused business model in a sector with favorable demographics. As LifeStance continues to scale and potentially achieve profitability, it could deliver strong returns for investors by 2026 through market share gains and operational efficiencies.

4

TALK

Talkspace, Inc. Common Stock
60.9
Score
$3.65
$452M
Company Overview

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of …

Why This Matters

Talkspace Inc. matters in the Health Services sector as a leading digital platform that democratizes access to behavioral healthcare, connecting users to licensed therapists, psychologists, and psychiatrists for various mental health conditions. By serving diverse clients including health plans, enterprises, and individual subscribers, it addresses the growing demand for scalable mental health solutions amid rising awareness and accessibility challenges.

Profitability Analysis

Talkspace's profitability is modest, with a profit margin of 2.0% indicating thin earnings relative to revenue, and an ROE of 3.7% suggesting limited efficiency in generating returns on equity. However, the company's strong revenue growth of 25.3% highlights its potential for scaling operations, though the high P/E ratio of 117.0 reflects high market expectations for future profitability amid current financial constraints.

2.0%
Profit Margin
3.7%
ROE
25.3%
Revenue Growth
117.0
P/E Ratio
Why It's a Buy in 2026

Talkspace's 25.3% revenue growth demonstrates robust demand for its digital mental health platform, positioning it to capitalize on the expanding behavioral health market by 2026 as telehealth adoption accelerates. The company's focus on serving health plans and enterprises could drive further market penetration and revenue diversification, potentially improving profitability. With a Tradestie Score of 60.9 indicating moderate investment appeal, the stock's high P/E ratio of 117.0 suggests investors are betting on sustained growth in mental health services, making it a compelling buy for those optimistic about the sector's long-term trends.

5

ATPC

Agape ATP Corporation Common Stock
58.7
Score
$0.10
$61M
Company Overview

Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness …

Why This Matters

Agape ATP Corp matters in the Health Services sector by supplying high-quality health and wellness products focused on cell metabolism, detoxification, and blood health, which align with the rising global demand for preventive healthcare solutions. Its 11.9% revenue growth highlights its ability to expand in a competitive market projected to grow due to increasing consumer awareness of wellness.

Profitability Analysis

Agape ATP Corp's profitability is severely challenged, with a profit margin of -182.6% indicating substantial losses relative to revenue, and an ROE of -21.6% showing inefficient use of shareholders' equity. However, the 11.9% revenue growth demonstrates top-line expansion, which could improve financial health if the company addresses its cost structure effectively.

-182.6%
Profit Margin
-21.6%
ROE
11.9%
Revenue Growth
Why It's a Buy in 2026

Investors should consider buying ATPC in 2026 due to its 11.9% revenue growth, signaling strong demand for its health products in a burgeoning wellness market expected to expand with demographic shifts. The Tradestie Score of 58.7 suggests moderate upside potential, and as the company leverages its focus on innovative supplements, it could achieve profitability amid sector-wide growth in preventive health services.

6

PIIIW

P3 Health Partners Inc. Warrant
57.6
Score
$0.01
--
Company Overview

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Why This Matters

P3 Health Partners Inc. matters in the Health Services sector due to its innovative patient-centered, physician-led population health management model, which aggregates community resources to deliver coordinated and integrated care, addressing the growing demand for value-based healthcare solutions amid rising chronic disease prevalence.

Profitability Analysis

With limited financial data available, P3 Health Partners' Tradestie Score of 57.6/100 indicates moderate financial health, suggesting potential stability in a competitive sector but highlighting the need for improved profitability metrics as the company scales its operations.

Why It's a Buy in 2026

By 2026, investors should consider PIIIW due to the projected growth in the Health Services sector, driven by an aging population and increasing adoption of population health management, where P3's model could capture significant market share. The company's physician-led approach may enhance operational efficiency and patient outcomes, potentially improving its Tradestie Score above 57.6 and driving stock value. Additionally, evolving healthcare policies favoring integrated care networks position P3 for revenue expansion and long-term profitability.

7

VSEE

VSee Health, Inc. Common Stock
56.1
Score
$0.43
$10M
Company Overview

VSee Health Inc is a telehealth software platform. VSee's telemedicine solution, offering a fast, secure text + video collaboration app HIPAA messenger, and fully customizable virtual waiting rooms and clinics, is a complete telehealth platform that fits into any workflow. The VSee proprietary technology platform and modular software solution enable users to plug and play telehealth services with end-to-end encrypted …

Why This Matters

VSee Health Inc. matters in the Health Services sector as its telehealth platform provides secure, customizable video and text collaboration tools that integrate seamlessly into healthcare workflows, addressing the rising demand for remote care solutions amid digital health adoption. With features like HIPAA-compliant messaging and virtual clinics, VSee positions itself as a vital enabler of efficient, accessible healthcare delivery in an increasingly virtual medical landscape.

Profitability Analysis

VSee Health's profitability is concerning, with a profit margin of -69.8% and a ROE of -259.6%, indicating substantial losses and poor returns on equity that highlight operational inefficiencies. However, the company's revenue growth of 18.7% suggests potential for scaling, though the low P/E ratio of 0.9 reflects market doubts about near-term earnings stability.

-69.8%
Profit Margin
-259.6%
ROE
18.7%
Revenue Growth
0.9
P/E Ratio
Why It's a Buy in 2026

VSee Health's 18.7% revenue growth demonstrates strong demand for its telehealth platform, positioning it for potential market share gains in the expanding digital health sector by 2026. The P/E ratio of 0.9 indicates the stock is undervalued, offering an attractive entry point for investors betting on profitability improvements through operational efficiencies. Additionally, with a Tradestie Score of 56.1/100, the company's moderate rating combined with telehealth trends could lead to significant upside as remote care adoption accelerates.

8

EUDA

EUDA Health Holdings Limited Ordinary Shares
56.0
Score
$2.39
$74M
Company Overview

EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security …

Why This Matters

EUDA Health Holdings Ltd stands out in the Health Services sector due to its innovative integration of property management services with holistic wellness offerings in high-growth regions like Southeast Asia and China, where it generates key revenue from these services. With a remarkable 60.2% revenue growth, the company is positioning itself as a key player in addressing the rising demand for non-invasive healthcare solutions in emerging markets.

Profitability Analysis

EUDA's profitability is modest, reflected in a 5.2% profit margin, indicating slim earnings relative to revenue amid operational costs in its segments. However, the company's strong financial health is evident from a 60.2% revenue growth, though the high P/E ratio of 123.0 suggests the stock may be overvalued compared to its earnings potential.

5.2%
Profit Margin
60.2%
Revenue Growth
123.0
P/E Ratio
Why It's a Buy in 2026

EUDA's 60.2% revenue growth highlights its potential for significant expansion in Southeast Asia and China by 2026, driven by increasing demand for integrated health and property services in these fast-growing markets. The company's focus on non-invasive healthcare and holistic wellness aligns with evolving consumer trends, potentially improving profitability beyond the current 5.2% margin. Additionally, with a Tradestie Score of 56.0, EUDA presents a viable investment opportunity for those seeking exposure to the Health Services sector's growth trajectory by 2026.

9

PNTG

The Pennant Group, Inc. Common Stock
56.0
Score
$28.44
$878M
Company Overview

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, …

Why This Matters

Pennant Group Inc. matters in the Health Services sector due to its specialized focus on serving the growing senior population through diversified offerings in home health, hospice, and senior living, addressing critical needs in an aging U.S. demographic. This positions the company as a key player in meeting the increasing demand for accessible and comprehensive healthcare services amid demographic shifts.

Profitability Analysis

Pennant Group's 3.1% profit margin indicates moderate profitability, reflecting slim margins in a competitive sector, while its 11.3% ROE demonstrates effective equity utilization for returns. The 26.8% revenue growth signals strong operational momentum, though the 37.1 P/E ratio suggests the stock is valued at a premium, potentially warranting caution on valuation relative to earnings.

3.1%
Profit Margin
11.3%
ROE
26.8%
Revenue Growth
37.1
P/E Ratio
Why It's a Buy in 2026

Pennant Group's 26.8% revenue growth, fueled by expanding demand in senior care, positions it for continued expansion by 2026 as the U.S. population ages. The 11.3% ROE underscores financial efficiency, supporting potential for enhanced profitability and shareholder returns. With its diversified services in home health and hospice, the company is well-placed to capitalize on demographic trends, making it an attractive buy for long-term investors.

10

OMDA

Omada Health, Inc. Common Stock
54.3
Score
$15.00
$1.3B
Company Overview

Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health …

Why This Matters

Omada Health matters in the Health Services sector as a leader in virtual care for chronic conditions like diabetes and hypertension, serving a growing market for personalized, tech-driven health solutions that improve patient outcomes and reduce healthcare costs. Its integrated platform addresses the rising demand for telehealth, positioning it as a key innovator amid increasing adoption of digital health services.

Profitability Analysis

Omada's negative profit margin of -19.8% highlights current unprofitability, likely due to high operational costs in scaling its virtual care platform, but this is offset by a strong revenue growth of 56.6%, indicating robust business expansion and potential for future financial health. The Tradestie Score of 54.3/100 suggests moderate investment appeal, reflecting a balance between high growth prospects and ongoing challenges in achieving profitability.

-19.8%
Profit Margin
56.6%
Revenue Growth
Why It's a Buy in 2026

Investors should consider buying OMDA stock in 2026 given its 56.6% revenue growth, which demonstrates strong demand for its virtual care services in managing chronic conditions like diabetes and hypertension, potentially leading to market leadership in telehealth. As the Health Services sector shifts toward digital solutions, Omada's personalized platform is well-positioned to capture increased adoption and improve margins through scale. Additionally, with a Tradestie Score of 54.3/100, the company's growth trajectory suggests it could deliver significant returns as profitability normalizes by 2026.

Methodology

Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.